Assessment of tuberculosis drug efficacy using preclinical animal models and in vitro predictive techniques
Abstract Tuberculosis (TB) killed approximately 1.3 million people in 2022 and remains a leading cause of death from the bacteria Mycobacterium tuberculosis (M.tb); this number of deaths was surpassed only by COVID-19, caused by the SARS-CoV-2 virus.The alarming emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) M.tb strain